ライフサイエンスコーパス: immunohistochemistry

1 g fluorescence imaging, autoradiography, and immunohistochemistry.

2 and correlated with the "gold standard" GPC3-immunohistochemistry.

3 mation of B cell clusters was assessed using immunohistochemistry.

4 mma2 was studied in the human amygdala using immunohistochemistry.

5 ole-cell voltage-clamp electrophysiology and immunohistochemistry.

6 asured using anti-gamma-H2A.X (phospho S139) immunohistochemistry.

7 sed postoperatively on biopsied tissue using immunohistochemistry.

8 cle tissue as determined by Western blot and immunohistochemistry.

9 in tumor, lung, and stomach was confirmed by immunohistochemistry.

10 rentiation, as assessed by Foxo1 and Aldh1a3 immunohistochemistry.

11 ns from BD patients and HCs was assessed via immunohistochemistry.

12 gions of human carotid arteries, examined by immunohistochemistry.

13 macrophages and neovessels was quantified by immunohistochemistry.

14 F and assessed intestinal differentiation by immunohistochemistry.

15 autoradiography ([(125)I]OVTA binding), and immunohistochemistry.

16 human normal and BC specimens was tested by immunohistochemistry.

17 was evaluated by using tissue microarray and immunohistochemistry.

18 compared with control via real-time PCR and immunohistochemistry.

19 reinstatement of alcohol-seeking using c-Fos immunohistochemistry.

20 2), at the protein level by western blot and immunohistochemistry.

21 means of flow cytometry, ELISA, Luminex, and immunohistochemistry.

22 cells or in tumour stroma, as determined by immunohistochemistry.

23 rradiation on brain tissues by histology and immunohistochemistry.

24 onal PPZ0506, specifically targets ERbeta in immunohistochemistry.

25 brosis were measured by quantitative PCR and immunohistochemistry.

26 epresenting chronic inflammation as shown by immunohistochemistry.

27 al and adult female mouse hypothalamus using immunohistochemistry.

28 on of selected molecules was confirmed using immunohistochemistry.

29 staining of prostatectomy specimens on PSMA immunohistochemistry.

30 ithout the invasive IPMN (control tissue) by immunohistochemistry.

31 by flow cytometry and on spleen sections by immunohistochemistry.

32 al panel of lymphatic endothelial markers by immunohistochemistry.

33 or and other tissues was determined by beta6 immunohistochemistry.

34 21 d by using quantitative real-time PCR and immunohistochemistry.

35 for apoptosis induction by cleaved caspase 3 immunohistochemistry.

36 expression in 1% or more of tumour cells by immunohistochemistry.

37 -were confirmed in the PROSPECT cohort using immunohistochemistry.

38 in in inhibitory nerve terminals revealed by immunohistochemistry.

39 Ki-67 expression was assayed by immunohistochemistry.

40 microenvironmental components as assessed by immunohistochemistry.

41 human splenic macrophages was identified by immunohistochemistry.

42 amined by RT-PCR, western blot analysis, and immunohistochemistry.

43 T cell infiltration was verified by immunohistochemistry.

44 ermined by microsatellite instability and/or immunohistochemistry.

45 nduced premalignant skin lesions assessed by immunohistochemistry.

46 oxidative damage markers using nitrotyrosine immunohistochemistry.

47 in TNBC (P = 0.01) was further validated by immunohistochemistry.

48 a function of PD-L1 expression determined by immunohistochemistry.

49 The identified genes were validated by immunohistochemistry.

50 and TCTP in gastric diseases was measured by immunohistochemistry.

51 eans of real-time PCR, Western blotting, and immunohistochemistry.

52 h chronic periodontitis (n = 2) was done via immunohistochemistry.

53 via Iba1 and P2X7R Western blotting and Iba1 immunohistochemistry.

54 ed weighted factors, which were confirmed by immunohistochemistry.

55 oderately to strongly positive for Trop-2 by immunohistochemistry.

56 fish (Neoceratodus forsteri), as revealed by immunohistochemistry.

57 These results were confirmed by immunohistochemistry.

58 controls) and analyzed them by histology and immunohistochemistry.

59 tissue levels (n = 6) by flow cytometry and immunohistochemistry.

60 holangiocyte proliferation were evaluated by immunohistochemistry.

61 ing, locked nuclei acid (LNA)-based PCR, and immunohistochemistry.

62 immunohistochemistry 2+/FISH nonamplified; 4 immunohistochemistry 1+).

63 men were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH amplified), whereas 7 were

64 2+/FISH amplified), whereas 7 were HER2- (3 immunohistochemistry 2+/FISH nonamplified; 4 immunohisto

65 Eleven women were HER2+ (8 immunohistochemistry 3+; 3 immunohistochemistry 2+/FISH

66 Using this marker, together with immunohistochemistry, acute slice electrophysiology, and

67 etermination of non-GCB DLBCL using the Hans immunohistochemistry algorithm, 206 patients were random

68 me, flow cytometry, electron microscopy, and immunohistochemistry analyses collectively highlight a l

69 The results of our immunohistochemistry analyses suggest that the zonal loc

70 as reflected by RT-PCR, Western blotting and immunohistochemistry analyses.

71 -201 for periablational phosphorylated STAT3 immunohistochemistry analysis at 24 hours.

72 Immunohistochemistry analysis confirmed elevated periabl

73 Transcriptomic studies and immunohistochemistry analysis demonstrate that NCoR1 pla

74 Quantitative RT-PCR and immunohistochemistry analysis identified that both FEN1

75 velopment and immune function via splenocyte immunohistochemistry analysis in association with ranavi

76 In line with the in vitro findings, immunohistochemistry analysis of lung adenocarcinoma sam

77 RG), optical coherence tomography (OCT), and immunohistochemistry analysis of R/G opsin and rhodopsin

78 cally, mast cell-IVD cell interactions using immunohistochemistry and 3D in-vitro cell culture method

79 In the present study, by combining immunohistochemistry and 3D ultrastructural analyses, we

80 Finally, immunohistochemistry and calcium imaging were used to as

81 We did TDP-43 immunohistochemistry and classified individuals as follo

82 le zebra finches, a combination of aromatase immunohistochemistry and conventional tract tracing faci

83 Bone marrow will be assessed by histology or immunohistochemistry and cytology or immunocytology.

84 ation of US28 in renal allograft biopsies by immunohistochemistry and determine its role in viral spr

85 Combined with the results from immunohistochemistry and electron microscope analysis, t

86 imaging properties, analyzed vasculature by immunohistochemistry and electron microscopy, and perfor

87 jury-induced collagen deposition detected by immunohistochemistry and elevation in Col1a1, FnEDA, and

88 ion to detect cancer-FOXP3 and Treg cells by immunohistochemistry and evaluated clinical and patholog

89 Accompanying evidence from immunohistochemistry and flow cytometry using antibodies

90 Immunohistochemistry and flow cytometry were used to ide

91 Tissue inflammation was assessed by immunohistochemistry and flow cytometry.

92 ction of membrane-bound TLN was confirmed by immunohistochemistry and fluorescence activated cell sor

93 ipids in rodent brain tissue with subsequent immunohistochemistry and fluorescent staining of histolo

94 e performed ex vivo pimonidazole-/HIF-1alpha immunohistochemistry and HIF-1alpha/2alpha Western blot/

95 Immunohistochemistry and histological and morphometric a

96 t human neurodegenerative diseases by ELISA, immunohistochemistry and immunoblots.

97 e distribution and extracellular assembly by immunohistochemistry and immunofluorescence microscopy.

98 Immunohistochemistry and immunofluorescence were used to

99 Additionally, immunohistochemistry and immunogold electron microscopy

100 Subtyping was performed with immunohistochemistry and in situ hybridization on tissue

101 onserved distribution patterns, we performed immunohistochemistry and in situ hybridization to locali

102 Immunohistochemistry and in situ hybridization were used

103 Immunohistochemistry and in vitro binding assays confirm

104 Using both immunohistochemistry and laser microdissection and press

105 Liver was analyzed by immunohistochemistry and mRNA levels were measured by qu

106 Analyses of p57 expression by immunohistochemistry and polymerase chain reaction-based

107 tein expression was assessed in 40 cases via immunohistochemistry and quantified by a novel 'composit

108 ialysis; probed neuronal activation by c-Fos immunohistochemistry and resting-state functional magnet

109 epithelial hyperplasia, and angiogenesis by immunohistochemistry and RT-PCR.

110 onstrated by validation with flow cytometry, immunohistochemistry and single-cell RNA-Seq analyses of

111 measured, retinal cell types were labeled by immunohistochemistry and the number of stained elements

112 tested in positive and negative controls by immunohistochemistry and uniplex IF, panels were develop

113 t brain areas by rabbit anti-PDE10A antibody immunohistochemistry and Western blotting.

114 Immunohistochemistry and x-ray fluorescence were used to

115 ymerase chain reaction), protein expression (immunohistochemistry), and infiltrating cell populations

116 d and then validated using western blotting, immunohistochemistry, and comparable TCGA RPPA datasets.

117 o 14.5 months old and analyzed by histology, immunohistochemistry, and electron microscopy.

118 maging, biodistribution, autoradiography and immunohistochemistry, and ex vivo HGF ELISA experiments

119 d by quantitative polymerase chain reaction, immunohistochemistry, and flow cytometry.

120 NanoString to amplify potential biomarkers, immunohistochemistry, and immunofluorescence, the ex viv

121 al injury as determined by light microscopy, immunohistochemistry, and intrarenal mRNA expression of

122 vel as revealed by in situ hybridization and immunohistochemistry, and is conserved in all Mabuya spe

123 1 gene-body methylation correlated with ASS1 immunohistochemistry, and longer arginine deprivation co

124 tex, we employed mRNA sequencing (mRNA-Seq), immunohistochemistry, and other approaches.

125 d autophagy were assessed by immunoblotting, immunohistochemistry, and qPCR.

126 t combines whole-cell patch-clamp recording, immunohistochemistry, and single-cell RNA-sequencing (sc

127 assical pharmacology, in situ hybridization, immunohistochemistry, and the Daun02 inactivation proced

128 es were collected, analyzed by histology and immunohistochemistry, and transcriptomes were compared b

129 olysaccharide-treated mice peaked by 72 h on immunohistochemistry, and Western blot analysis of P2X7R

130 through transcriptomics and high-throughput immunohistochemistry-based approaches, where over 40 000

131 2NLS(tm) and wild type mice were analyzed by immunohistochemistry, behavioral tests, and electrophysi

132 Other immunohistochemistry biomarkers were not associated with

133 Diagnosis is made using immunohistochemistry, but molecular testing with mutatio

134 Using immunohistochemistry, calcium imaging, electrophysiology

135 en the hearts were removed and processed for immunohistochemistry (CD68, CD206, FOXP3), cytokines (IL

136 Immunohistochemistry confirmed aging-induced rarefaction

137 Immunohistochemistry confirmed cathepsin K protein was e

138 This study used multiple labeling immunohistochemistry, confocal maging and analysis to in

139 d replication cohort (12 and eight pairs) by immunohistochemistry-confocal microscopy.

140 Following immunohistochemistry, CYP11B2-expressing area and areas

141 tions of liver mass, enzymatic activity, and immunohistochemistry demonstrate that damaged lobes unde

142 Immunohistochemistry demonstrated increased GOT protein

143 Immunohistochemistry demonstrated that CDX2 and TCTP exp

144 Immunohistochemistry detected high expression of PHD2 in

145 histology, immunoblots, phalloidin staining, immunohistochemistry, electron microscopy, and flow cyto

146 Glycan microarrays complemented with immunohistochemistry elucidated the nature of compositio

147 ption polymerase chain reaction, immunoblot, immunohistochemistry, enzyme-linked immunosorbent assays

148 Immunohistochemistry experiments and whole-cell current

149 Immunohistochemistry for ADK served as a biomarker appro

150 We used immunohistochemistry for calretinin and neuropeptide Y i

151 gical resection, and tumor samples underwent immunohistochemistry for IDH-1 R132H mutations.

152 Tumor tissues were analyzed by immunohistochemistry for levels of SMAD4, BMPR1A, BMPR1B

153 terns of taste-induced activity, we combined immunohistochemistry for markers of various visceral aff

154 Lymph2Cx assay for COO classification, with immunohistochemistry for MYC and BCL2, and with fluoresc

155 Immunohistochemistry for MYC, BCL2, and BCL6 and fluores

156 glycoprotein (Mog) and ermin (Ermn), and by immunohistochemistry for myelin basic protein.

157 Immunohistochemistry for NKCC1, KCC2, and ectopic recurr

158 Notch1 activation was assessed by immunohistochemistry for Notch1 intracellular domain.

159 Immunohistochemistry for putative M-current candidates s

160 arrier 14 days after antibody injection, and immunohistochemistry for rabbit IgG and THSD7A as well a

161 Human lungs were assessed by using immunohistochemistry for SIRT3 activity via acetylated M

162 Immunohistochemistry for the gamma aminobutyric acid syn

163 rapy, we screened invasive breast cancers by immunohistochemistry for the presence and intensity of G

164 minimum requirement of FRalpha positivity by immunohistochemistry (>/= 25% of tumor cells with at lea

165 We used western blots, immunohistochemistry, H&E and biochemical enzyme assays

166 Electrophysiological recordings and c-Fos immunohistochemistry have shown the existence of sleep-a

167 re collected and analyzed by immunoblotting, immunohistochemistry, histology, and real-time polymeras

168 ASS1 immunohistochemistry identified all the UHCA, of which 6

169 Immunohistochemistry identified elevated ENPP1 expressio

170 ] of 2,558; P < .001), and the proportion of immunohistochemistry (IHC) 2+ tumors was significantly l

171 Immunohistochemistry (IHC) analysis of sow tissue sample

172 istologic lesions typical of PDNS in sows by immunohistochemistry (IHC) analysis.

173 Whereas immunohistochemistry (IHC) and immunoassays are routinel

174 The assessment of protein expression in immunohistochemistry (IHC) images provides important dia

175 FOXP1 and assessed its protein expression by immunohistochemistry (IHC) in 763 tissue biopsies.

176 Further experiments of immunohistochemistry (IHC) showed increased expression o

177 Herein, we utilized immunohistochemistry (IHC) staining and public microarra

178 ), antigen capture enzyme immunoassay (EIA), immunohistochemistry (IHC), and in vitro real-time quaki

179 We have studied by histology, immunohistochemistry (IHC), electron microscopy and neur

180 stuzumab as measured by PET/CT and standard, immunohistochemistry (IHC)-based, histopathologic classi

181 analyzed for prion infection post-mortem by immunohistochemistry (IHC).

182 ts with moderate to high COX-2 expression by immunohistochemistry (IHC).

183 tin-19 expression and proliferation by Ki-67 immunohistochemistry (IHC).

184 ovaries and testis and confirmed by qPCR and immunohistochemistry (IHC).

185 litis development and analyzed by histology, immunohistochemistry, immunoblots, or ELISAs (to measure

186 Using a combination of immunohistochemistry, immunofluorescence and neural trac

187 nts of the following: in situ hybridization, immunohistochemistry, immunofluorescence by conventional

188 Immunohistochemistry, immunofluorescence, and Western bl

189 re analyzed with light and video microscopy, immunohistochemistry, immunofluorescence, cell viability

190 Thus, nKIFC1 expression was assessed by immunohistochemistry in 163 African American (AA) and 14

191 ers (pRPA32 and gamma-H2AX) was evaluated by immunohistochemistry in 289 MBC samples to assess their

192 ly confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck s

193 trophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n =

194 NRG-GBM-RPA) was confirmed using traditional immunohistochemistry in an independent data set (n = 176

195 d by ELISA in bronchial/nasal lysates and by immunohistochemistry in bronchial tissue obtained from s

196 L-22(+), and IL-23(+) cells were examined by immunohistochemistry in cryostat sections of bronchial/n

197 eosinophils were detected and quantified by immunohistochemistry in endobronchial biopsy sections fr

198 Immunohistochemistry in kidney sections from these patie

199 The DR was evaluated by cytokeratin-7 immunohistochemistry in liver biopsies, staged for fibro

200 hy showed excellent spatial correlation with immunohistochemistry in mixed tumors.

201 3, SOX2, and CD44 expression was detected by immunohistochemistry in pretreatment tumor biopsies, and

202 chanism of any plaque DOTATATE activity with immunohistochemistry in resected specimens.

203 evels in the NAc were assessed via ELISA and immunohistochemistry (in neurons, astrocytes, and microg

204 Immunohistochemistry, including temporal analyses, demon

205 One such method is immunohistochemistry, increasingly popular because it is

206 Immunohistochemistry indicated that LAMB4 localizes to t

207 Immunohistochemistry localized ACVR2A and ACVR2B to oste

208 Immunohistochemistry localized MAP3K14 expression to tub

209 fected HEK293T cells through immunoblotting, immunohistochemistry, luciferase activity, real-time pol

210 usively in HCs by proteomics and verified by immunohistochemistry map to human genetic deafness loci,

211 However, TP53 and SOX11 immunohistochemistry might improve risk stratification.

212 ted control (SHAM) rats, in conjunction with immunohistochemistry, myelin staining, and a novel three

213 using gene expression analysis (N = 60) and immunohistochemistry (N = 56) the study demonstrates exp

214 ients strongly positive for HER1/HER2 (3+ on immunohistochemistry; n = 111), patients positive for on

215 The present study combines immunohistochemistry, neural tract tracing, and electron

216 ce in situ hybridization (FISH)-supplemented immunohistochemistry of biopsied tumor tissue.

217 Additional ex vivo measurements and immunohistochemistry of cervicomedullary metastasis samp

218 Alizarin red staining and immunohistochemistry of GFP and osteocalcin further indi

219 growth in vitro and tumor formation in vivo Immunohistochemistry of patient tumor samples revealed t

220 Gene expression (qPCR) analysis and immunohistochemistry of the palmar epidermis demonstrate

221 D-L1 positivity was defined as expression by immunohistochemistry on >/= 5% of tumor cells.

222 n and cellular localization of CEACAM6 using immunohistochemistry on bronchial biopsy tissue obtained

223 rotein expression on cells and validation by immunohistochemistry on human tissue specimens justified

224 We measured the presence of villin 1 by immunohistochemistry on kidney sections and by Western b

225 Immunohistochemistry on murine retinae revealed an overl

226 We performed SOX11 and TP53 immunohistochemistry on the so far largest published coh

227 Claudin-2 expression was examined by immunohistochemistry on tissue microarrays, containing E

228 ed it to detect PD-L1 expressing tumors with immunohistochemistry or flow cytometry.

229 and application of an eight-color multiplex immunohistochemistry panel, consisting of PD-1, PD-L1, O

230 CD3- and B220-postive lymphocytes by double immunohistochemistry (PCNA-staining) and flow cytometry

231 rogression-free survival in the PTEN-low (by immunohistochemistry) population.

232 te the molecular response to Wnt stimuli and immunohistochemistry, proliferation, and cell death assa

233 es were harvested and examined by histology, immunohistochemistry, quantitative RT-PCR, ELISA, and fl

234 Biochemical analysis, histology, and immunohistochemistry results showed the deposition of AF

235 Immunohistochemistry results were then compared with ex

236 ecursor using mRNA in situ hybridization and immunohistochemistry revealed a widespread distribution,

237 rubens using mRNA in situ hybridization and immunohistochemistry revealed a widespread pattern of ex

238 tomographic pulmonary angiography and Ki-67 immunohistochemistry revealed abundant lung neovasculari

239 Immunohistochemistry revealed altered OPN and DMP1 assoc

240 Immunohistochemistry revealed staining for CM, FB and EC

241 Immunohistochemistry revealed US28 in 31 of 34 renal tra

242 in vivo expression analysis by RNAscope and immunohistochemistry reveals some salt and pepper patter

243 anization of these induced structures, while immunohistochemistry reveals the presence of rudimentary

244 and tissues were characterized by histology, immunohistochemistry, RNA sequencing, and whole-exome se

245 egrates data from RNA in situ hybridization, immunohistochemistry, RT-PCR, northern blot and western

246 Immunohistochemistry showed activation of microglia and

247 Double-staining immunohistochemistry showed CXCL9 co-localized with CD68

248 Histopathology and immunohistochemistry showed mucosa-associated lymphoid t

249 Expression profiling on human embryos by immunohistochemistry showed strong expression of hFOXA2

250 Surprisingly, immunohistochemistry showed that high-CE and vessel numb

251 Quantitative PCR and immunohistochemistry showed that HOXB13 gene and protein

252 kB.T1-driven astrocytes in vitro and in vivo Immunohistochemistry showed that trkB.T1(+) cells were s

253 and metastases of an endometrial carcinoma, immunohistochemistry showed THSD7A expression on the met

254 r absence in normal liver was established by immunohistochemistry staining and mass spectrometric ana

255 without AD were evaluated, using genomic and immunohistochemistry studies, against intrapersonal cont

256 /dead staining, cell proliferation assay and immunohistochemistry study of human corneal epithelial c

257 transcription polymerase chain reaction and immunohistochemistry subsequently confirmed the presence

258 These results were verified by immunohistochemistry, suggesting that GalNAc-T6 plays a

259 Using immunohistochemistry TBK1 protein was predominantly loca

260 Cell markers were analyzed by using immunohistochemistry, the Luminex Multiplex assay, ELISA

261 By immunohistochemistry, the number of CXCR3-positive monon

262 On the basis of cytoarchitecture and immunohistochemistry, the sensory trigeminal column can

263 We used immunohistochemistry to assess oncoprotein encoded by th

264 c examination of gingival and liver tissues; immunohistochemistry to cells positive for neural/glial

265 o identify epileptic animals and post-mortem immunohistochemistry to confirm blood-brain barrier dysf

266 cted from mice and analyzed by histology and immunohistochemistry to detect mucin 2, as well as by 16

267 ional morphea skin, and used double-staining immunohistochemistry to determine the cutaneous cellular

268 We then used immunohistochemistry to determine whether GPR30 colocali

269 ew presents the case for conducting receptor immunohistochemistry to evaluate potential molecular tar

270 We used transmission electron microscopy and immunohistochemistry to evaluate this claim in five rapt

271 We used latexin immunohistochemistry to identify claustral boundaries an

272 tion and used early growth response factor 1 immunohistochemistry to identify potential sites of OTR

273 d with the loss of the eggshell, and we used immunohistochemistry to report that this reaction occurs

274 We also applied immunohistochemistry to study beta-amyloid and activated

275 (RT-QuIC) and tyramide signal amplification immunohistochemistry (TSA-IHC).

276 Immunohistochemistry using a biotin-modified peptide (RK

277 s, which can be quite reliably identified by immunohistochemistry using the CM2B4 antibody alone, rep

278 ons of the same biopsy were then examined by immunohistochemistry, using 2 different monoclonal antib

279 Glucose transporter 1 (GLUT1) immunohistochemistry was performed to assess whether (18

280 brain slice electrophysiology, behavior, and immunohistochemistry was used to advance the novel conce

281 Post-hoc immunohistochemistry was used to confirm cell identity.

282 Using conventional immunohistochemistry, we assessed in rats and mice the s

283 Using immunohistochemistry, we found that 90% of ERbeta-immuno

284 Using Ddr2 LacZ-tagged mice and immunohistochemistry, we found that DDR2 is preferential

285 s in immune responses to S. venezuelensis By immunohistochemistry, we found that numbers of basophils

286 Using immunohistochemistry, we have shown the apoplastic prese

287 Using immunohistochemistry, we observed spatiotemporal regulat

288 picrosirius red staining, and CD31 and CD34 immunohistochemistry were applied to TMA sections.

289 Morphology and immunohistochemistry were most consistent with pulmonary

290 polymerase chain reaction, Western blot, and immunohistochemistry were used to analyze secreted frizz

291 vivo microCT monitored healing over time and immunohistochemistry were used to track the fate of dono

292 e biomarkers (determined by using RT-PCR and immunohistochemistry) were evaluated.

293 Immunohistochemistry, Western blot, and qRT-PCR were per

294 Postmortem, organs were sampled for immunohistochemistry, western blotting, and mitochondria

295 were highly positive (2+, 3+) for Trop-2 by immunohistochemistry, which suggests that Trop-2 is not

296 However, multiplex immunohistochemistry with a maximized number of markers

297 ry GN specimens only, immunofluorescence and immunohistochemistry with an anti-DNAJB9 antibody showed

298 Immunohistochemistry with the CM2B4 antibody had the bes

299 ies, we detected MCPyV large T antigen using immunohistochemistry with two distinct antibodies and MC

300 asthmatic (n = 27) bronchial biopsies using immunohistochemistry, with a semi-quantitative score def